Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Betavit is a commercial consumer healthcare product developed and marketed by Petrus Pharmaceuticals, primarily in the Australian market. It is formulated as an oral capsule containing 6 mg of betacarotene, a provitamin A carotenoid. Betacarotene is a lipid-soluble pigment that the human body converts into Vitamin A (retinol) as needed, making it a safe source of the vitamin without the high risk of toxicity associated with preformed Vitamin A. It plays a critical role in maintaining ocular health, supporting the immune system, and promoting healthy skin and mucous membranes. Additionally, betacarotene acts as a potent antioxidant, neutralizing free radicals and protecting tissues from oxidative stress. In Australia, it is listed on the Australian Register of Therapeutic Goods (ARTG) as a complementary medicine for nutritional supplementation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on betacarotene.